ANSWER: B

Rationale:

Option B is correct. Testosterone circulates predominantly protein-bound: approximately 60% to 70% tightly bound to sex hormone-binding globulin (SHBG), approximately 25% to 35% loosely bound to albumin, and only 1% to 3% free (unbound). Only the free and albumin-bound fractions are biologically available to tissues, because SHBG-bound testosterone is not released to cells for receptor binding. Total testosterone measurements capture all three fractions. When SHBG is markedly reduced — as occurs in obesity, insulin resistance, type 2 diabetes, and hypothyroidism — total testosterone falls proportionally because less testosterone is stabilized in the SHBG-bound pool. In this scenario, total testosterone may read borderline low or frankly low while the bioavailable testosterone (free + albumin-bound) remains relatively preserved; alternatively, in a patient whose androgen deficiency is genuine, the low total testosterone may understate how little bioavailable testosterone is present because the SHBG disturbance has shifted the distribution. Clinical evaluation therefore requires calculated free testosterone or direct free testosterone measurement when SHBG disturbance is suspected, not reliance on total testosterone alone.

• Option A: Option A is incorrect; SHBG does not regulate hepatic clearance of testosterone — it is a transport protein, not a metabolic enzyme or clearance mediator, and reduced SHBG does not increase hepatic testosterone degradation.
• Option C: Option C is incorrect; SHBG does not stimulate pituitary LH secretion. LH is regulated by GnRH pulse frequency and estradiol/testosterone negative feedback, not by circulating SHBG levels.
• Option D: Option D is incorrect; aromatization of testosterone to estradiol is catalyzed by CYP19A1 (aromatase) in peripheral tissues, particularly adipose tissue. SHBG levels do not directly regulate aromatase activity. While obesity increases aromatization and reduces SHBG, these are parallel consequences of adiposity rather than a causal chain in which SHBG drives aromatase.
• Option E: Option E is incorrect; SHBG is a plasma transport protein and does not enter cells or compete with androgen binding at the intracellular androgen receptor. The AR resides in the cytoplasm and nucleus; SHBG operates entirely in the extracellular compartment.

ANSWER: D

Rationale:

Option D is correct. Dihydrotestosterone (DHT) is formed by intracellular 5 alpha-reduction of testosterone in tissues expressing 5 alpha-reductase (5AR), particularly the prostate, seminal vesicles, skin, scalp hair follicles, and liver. DHT binds the androgen receptor (AR) with approximately 3 to 5 times greater affinity than testosterone and produces a more stable AR-DHT complex that has a slower dissociation rate, resulting in more prolonged nuclear occupancy and stronger activation of androgen response elements (AREs) driving gene transcription. This pharmacodynamic distinction explains the tissue-selective effects of 5AR inhibitors: by reducing DHT production in the prostate and scalp while leaving testosterone intact, finasteride and dutasteride selectively attenuate androgenic stimulation in DHT-dependent tissues without abolishing testosterone-mediated effects on muscle, bone, and erythropoiesis, which are driven predominantly by testosterone itself.

• Option A: Option A is incorrect; DHT is not a prodrug requiring reconversion to testosterone. DHT is itself the active androgen — it acts directly at the AR. Reconversion of DHT to testosterone does not occur at the AR, and the 17-beta-hydroxysteroid dehydrogenase enzymes catalyze androstenedione-to-testosterone conversions, not DHT-to-testosterone conversions at the receptor.
• Option B: Option B is incorrect; DHT, like testosterone, acts through the classical cytoplasmic nuclear receptor (AR), which translocates to the nucleus and binds AREs in androgen-regulated gene promoters. Neither DHT nor testosterone acts primarily through membrane-bound G protein-coupled receptors in canonical androgen signaling.
• Option C: Option C is incorrect; DHT and testosterone do not have identical AR binding affinities — this is the key pharmacodynamic distinction between the two. DHT has substantially higher affinity.
• Option E: Option E is incorrect that the non-aromatizability of DHT "enhances androgenic potency" through estrogenic mechanisms. While it is true that DHT cannot be aromatized to estradiol, this property has no direct effect on DHT's affinity for the AR or on competing estrogenic feedback at the AR. The potency of DHT derives from its higher AR binding affinity and receptor stability, not from estrogenic competition.

ANSWER: A

Rationale:

Option A is correct. The two principal 5 alpha-reductase isoforms have distinct tissue distributions that are pharmacologically important. Type 2 5AR, encoded by SRD5A2, is expressed predominantly in the prostate, seminal vesicles, epididymis, scalp hair follicles, and external genitalia, and is responsible for the majority of intraprostatic dihydrotestosterone (DHT) production — the primary androgen driving prostatic epithelial and stromal proliferation in BPH and prostate cancer. Type 1 5AR, encoded by SRD5A1, is expressed predominantly in the liver, skin, sebaceous glands, and other peripheral tissues. Finasteride's approximately 100-fold selectivity for the type 2 isoform concentrates its DHT-reducing effect at the prostate (where it reduces intraprostatic DHT by over 90% and serum DHT by approximately 70%) and at the scalp (where it reduces scalp DHT by approximately 65%). Because finasteride has minimal activity against type 1, it incompletely suppresses systemic DHT compared to dutasteride.

• Option B: Option B is incorrect; it inverts the isoform-to-tissue assignments entirely. Type 2 is the prostatic isoform; type 1 is the peripheral/hepatic isoform.
• Option C: Option C is incorrect; the two isoforms are not expressed equally in the prostate. Type 2 predominates in prostatic tissue, and finasteride's type 2 selectivity produces clinically meaningful intraprostatic DHT suppression. The premise that dutasteride is always preferred is also inaccurate — head-to-head trials have not demonstrated meaningful superiority of dutasteride over finasteride for BPH outcomes.
• Option D: Option D is incorrect; type 2 5AR is not responsible for peripheral estradiol production. Estradiol is produced from testosterone by aromatase (CYP19A1), not by 5 alpha-reductase. Finasteride does not affect estradiol levels through this mechanism.
• Option E: Option E is incorrect; the two isoforms have distinctly different tissue distributions, not identical distributions. The selectivity is a pharmacodynamic distinction based on enzyme structure and catalytic activity, not simply a pharmacokinetic one.

ANSWER: C

Rationale:

Option C is correct. The phenotype of congenital SRD5A2 deficiency illustrates the tissue-selective roles of testosterone versus dihydrotestosterone (DHT) in male sexual differentiation. During fetal development, testosterone drives differentiation of the wolffian ducts into the epididymis, vas deferens, and seminal vesicles (internal male structures), while DHT — produced locally by type 2 5AR from testosterone — is required for virilization of the urogenital sinus and genital tubercle into the male external genitalia (penis, scrotum). In a 46,XY individual with SRD5A2 deficiency, testosterone production is intact, so internal male structures develop normally. However, the lack of DHT in fetal external genital tissue results in failure of external virilization, producing ambiguous or female-appearing external genitalia at birth. At puberty, the surge in testosterone production — now at concentrations orders of magnitude higher than fetal levels — partially compensates for the absent DHT effect through direct androgen receptor (AR) activation, producing dramatic phallic enlargement, testicular descent, and virilization of external structures. This phenotype was first described by Imperato-McGinley and colleagues and provides the clinical proof-of-concept for the tissue-selective roles of the two androgens.

• Option A: Option A is incorrect; SRD5A2 deficiency does not cause precocious puberty. Gonadotropin secretion is regulated by GnRH pulse frequency and testosterone/estradiol negative feedback, not by DHT levels.
• Option B: Option B is incorrect; testosterone alone is not sufficient for male external genital virilization in utero. The male external genitalia specifically require DHT produced locally by type 2 5AR, as demonstrated by the female-appearing or ambiguous external genitalia in SRD5A2 deficiency despite normal testosterone.
• Option D: Option D is incorrect; internal male structures (vas deferens, epididymis, seminal vesicles) develop from the wolffian ducts under testosterone stimulation and do NOT require DHT. SRD5A2 deficiency therefore produces absent or abnormal external genitalia but normal internal male structures — the opposite of what option D describes.
• Option E: Option E is incorrect; SRD5A2 deficiency does not cause accelerated prostatic hypertrophy. In fact, these individuals have markedly reduced prostate size, and clinical observation of their low prostate cancer incidence and BPH rates provided the original rationale for developing finasteride as a treatment.

ANSWER: E

Rationale:

Option E is correct. Testosterone enanthate is a long-chain ester prodrug in which the 17-beta hydroxyl group of testosterone is esterified with enanthic acid. Following intramuscular injection into the oily depot, it is slowly absorbed and the ester is cleaved by serum esterases to release free testosterone. Peak serum testosterone concentrations typically occur 24 to 72 hours after injection, reaching supraphysiological levels early in the dosing interval. With a half-life of approximately 7 to 8 days, biweekly (every-14-day) dosing allows concentrations to fall substantially — in many patients to sub-normal levels — before the next injection. This pronounced peak-to-trough pharmacokinetic variation is the mechanistic basis for the cyclical symptom pattern this patient describes: feeling well shortly after injection (during the supraphysiological peak) and experiencing androgen-deficiency symptoms before the next dose (during the trough). The clinical solution is to switch to weekly injections of the same total dose (e.g., 100 mg weekly), which reduces peak-to-trough fluctuation substantially, or to transition to a more pharmacokinetically stable formulation such as a transdermal gel.

• Option A: Option A is incorrect; testosterone enanthate does not have a 12-hour half-life. Its half-life of approximately 7 to 8 days is what produces the biweekly dosing schedule. A 12-hour half-life would be characteristic of a rapid-acting non-esterified preparation.
• Option B: Option B is incorrect; testosterone enanthate undergoes ester cleavage by non-hepatic serum and tissue esterases, not hepatic activation. It does not require hepatic first-pass bioactivation, and the cleavage is predictable and efficient.
• Option C: Option C is incorrect; testosterone enanthate is reliably absorbed from the intramuscular depot and achieves therapeutic testosterone levels. The problem is the reverse: levels are supraphysiological at peak, not subtherapeutic.
• Option D: Option D is incorrect; the key feature of biweekly testosterone enanthate is its significant peak-to-trough fluctuation, not pharmacokinetic stability. Stable testosterone levels are a feature of daily transdermal preparations, not biweekly IM ester injections.

ANSWER: B

Rationale:

Option B is correct. Oral testosterone undecanoate is distinguished from earlier oral androgen preparations by its absorption pathway. The long undecanoate ester chain makes the molecule sufficiently lipophilic to be packaged into intestinal chylomicrons — the large lipoprotein particles formed in enterocytes during fat digestion and secreted into the intestinal lymphatics (thoracic duct) rather than the portal venous system. This lymphatic absorption route bypasses the liver on the first pass, allowing testosterone undecanoate to enter the systemic circulation intact and be cleaved by serum esterases to release free testosterone. Dietary fat is essential because chylomicron synthesis and secretion by enterocytes is driven by the presence of dietary triglycerides and fatty acids; without at least a moderate fat content in the meal, chylomicron formation is insufficient, and testosterone undecanoate is absorbed by the paracellular or transcellular portal route and undergoes extensive hepatic first-pass metabolism, resulting in very low bioavailability. Earlier oral androgen formulations — particularly methyltestosterone and stanozolol — required addition of a methyl group at the C17-alpha carbon to prevent hepatic oxidation at the 17-beta hydroxyl, conferring portal-route oral bioavailability but at the cost of severe intrahepatic cholestasis and hepatotoxicity. Oral testosterone undecanoate avoids hepatotoxicity precisely because it bypasses the portal-hepatic axis through the lymphatic route.

• Option A: Option A is incorrect; the lymphatic absorption of testosterone undecanoate is not related to bile acid-mediated esterase activation. Ester cleavage occurs via serum esterases in the systemic circulation, not hepatic enzymes.
• Option C: Option C is incorrect; CYP3A4 inhibition by dietary fat is not the mechanism of absorption for testosterone undecanoate. While fatty foods can modestly inhibit gut wall CYP3A4 for some drugs, this is not the mechanism governing testosterone undecanoate's absorption requirement.
• Option D: Option D is incorrect; oral testosterone undecanoate is a lipid-soluble molecule in an oily soft-gelatin capsule formulation, not a lipid emulsion requiring bile salt-mediated solubilization in the way bile acids solubilize dietary lipids.
• Option E: Option E is incorrect; no specific ATP-binding cassette (ABC) transporter has been identified as the governing absorption mechanism for oral testosterone undecanoate. The duodenum-specific transporter premise is inaccurate; lymphatic absorption occurs along the small intestine wherever chylomicron formation is active during fat digestion.

ANSWER: D

Rationale:

Option D is correct. Testosterone undecanoate 1,000 mg IM (Nebido) is formulated in castor oil in a volume of 4 mL, which must be administered by deep gluteal intramuscular injection by a qualified healthcare professional. The requirement for a mandatory 30-minute post-injection observation period is mandated by regulatory agencies and prescribing information due to the risk of pulmonary oil microembolism (POME), a serious adverse reaction arising from inadvertent intravascular injection or from rapid absorption of the oily vehicle into venous capillaries at the injection site. POME manifests as acute respiratory symptoms — cough, dyspnea, chest tightness, chest pain — along with cardiovascular symptoms including dizziness and syncope, typically occurring within minutes to 30 minutes of injection. The large injection volume (4 mL) of castor oil contributes to this risk. This 30-minute observation requirement is specific to testosterone undecanoate IM and does not apply to testosterone enanthate or cypionate, which are administered in smaller volumes with different oily vehicles. Anaphylaxis is an additional reason for the observation period.

• Option A: Option A is incorrect; POME does not present as orthostatic hypotension from vasodilation, and the recommended observation is 30 minutes, not 60. The primary concern is respiratory/embolic symptoms, not vasodilatory hypotension.
• Option B: Option B is incorrect; a serum testosterone level at 30 minutes post-injection has no clinical utility for confirming depot absorption, as peak testosterone from the undecanoate formulation does not occur until days later, and intravenous injection would be confirmed by immediate adverse symptoms, not a serum level.
• Option C: Option C is incorrect; prophylactic antihistamines are not mandated for Nebido administration, and a 10% first-injection hypersensitivity rate attributable to benzyl benzoate is not established in the prescribing data for this formulation.
• Option E: Option E is incorrect; while patients should avoid vigorous rubbing of the injection site, there is no established restriction on physical activity related to preventing premature depot dissolution from Nebido injections.

ANSWER: A

Rationale:

Option A is correct. Transdermal testosterone gels carry a well-established and FDA-labeled risk of secondary exposure: testosterone can transfer from the application site to other persons through direct skin-to-skin contact or indirectly through contact with contaminated clothing, towels, or surfaces. Post-marketing reports and case series have documented virilization in female partners of testosterone gel users, including clitoromegaly, hirsutism, voice changes, and menstrual irregularity, as well as pseudoprecocious puberty in young children (penile or clitoral enlargement, pubic hair, acceleration of bone age) following household exposure. Risk mitigation requires washing hands immediately after application, covering the application site with clothing once the gel has dried, avoiding direct skin-to-skin contact with the treated area for at least several hours after application, and showering before anticipated contact if possible. This secondary exposure risk does not apply to intramuscular or subcutaneous testosterone formulations, which is a meaningful pharmacological advantage of those delivery routes for men with children or female partners in the home.

• Option B: Option B is incorrect; transdermal testosterone bypasses hepatic first-pass metabolism entirely by crossing the skin directly into the systemic circulation. Hepatotoxicity from transdermal gels has not been established, and CYP3A4 interactions are not a primary concern for this route.
• Option C: Option C is incorrect; local skin necrosis is not a recognized adverse effect of testosterone gel. Mild skin irritation or dryness from the alcohol vehicle can occur but is not necrosis, and the rotation schedule described is not standard guidance for gel formulations.
• Option D: Option D is incorrect; prepubertal children are not protected from exogenous androgens by lack of hypothalamic-pituitary-gonadal axis maturity. Androgens exert direct tissue effects on androgen receptor-expressing tissues (external genitalia, adrenal axis, bone growth plates) in children regardless of HPG axis maturity, which is why virilization of young children from household testosterone gel exposure has been documented.
• Option E: Option E is incorrect; transdermal gel does not produce higher estradiol than injectable formulations as a result of cutaneous aromatization, and it is not associated with substantially elevated thrombotic risk compared to injectable testosterone.

ANSWER: C

Rationale:

Option C is correct. Erythrocytosis (polycythemia) is the most common dose-dependent adverse effect of testosterone replacement therapy (TRT), occurring in approximately 20% to 40% of men on injectable formulations. Testosterone stimulates erythropoiesis through multiple mechanisms: androgen receptor (AR)-mediated stimulation of erythroid progenitor cells in bone marrow, suppression of hepcidin (a hepatic regulatory peptide that limits iron availability), and increased erythropoietin production. The established clinical threshold for action is a hematocrit above 54% (equivalent to a hemoglobin above 18.5 g/dL), at which point guideline-directed management recommends one of three interventions: dose reduction, formulation change to a transdermal preparation (which produces lower and more stable testosterone levels with less erythrocytogenic stimulus than biweekly injectable formulations), or therapeutic phlebotomy to directly reduce the erythrocyte mass. The rationale for intervention is that hematocrit above 54% significantly increases whole-blood viscosity, producing a prothrombotic milieu that elevates the risk of both venous thromboembolism and arterial events including stroke and myocardial infarction. This patient's hematocrit of 56% with accompanying headaches (a symptom of hyperviscosity) clearly meets the threshold for action.

• Option A: Option A is incorrect; erythrocytosis above the 54% hematocrit threshold requires active management, not watchful waiting. The 54% threshold is not arbitrary — it reflects the level at which viscosity-related thrombotic risk becomes clinically significant.
• Option B: Option B is incorrect; permanent discontinuation of TRT is not required for hematocrit elevation. Dose reduction or formulation change is typically effective, and most patients can remain on TRT with appropriate adjustment.
• Option D: Option D is incorrect; antiplatelet therapy does not address the core mechanism of the thrombotic risk in erythrocytosis, which is hyperviscosity from elevated red cell mass. There is no established evidence that aspirin substitutes for dose adjustment or phlebotomy in TRT-related erythrocytosis.
• Option E: Option E is incorrect; while polycythemia vera should be considered in the differential diagnosis of erythrocytosis, a bone marrow biopsy is not required before attributing hematocrit elevation to TRT in a man who is known to be on injectable testosterone therapy and has no other features suggesting a myeloproliferative neoplasm. Appropriate initial evaluation includes measurement of serum erythropoietin (low in polycythemia vera, elevated or normal in secondary erythrocytosis), not immediate bone marrow biopsy.

ANSWER: E

Rationale:

Option E is correct. The TRAVERSE (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men) trial was a randomized, double-blind, placebo-controlled trial specifically designed to address the cardiovascular safety question that had been raised by earlier observational studies and the prematurely stopped TOM (Testosterone in Older Men with Mobility Limitations) trial. TRAVERSE enrolled 5,246 men aged 45 to 80 with hypogonadism and elevated cardiovascular risk (pre-existing cardiovascular disease or significant cardiovascular risk factors) and followed them for a mean of 33 months. The primary cardiovascular endpoint — a composite of major adverse cardiovascular events (MACE) including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death — was non-inferior in the testosterone group compared to placebo, resolving the question of whether TRT is broadly cardiotoxic in this population. However, TRAVERSE identified specific secondary safety signals: testosterone was associated with increased rates of atrial fibrillation (3.5% vs 2.4%), pulmonary embolism (0.9% vs 0.5%), and acute kidney injury. These findings, along with the established erythrocytosis risk, inform current monitoring protocols and reinforce the contraindication of TRT in men with recent myocardial infarction or stroke (within 6 months) or advanced heart failure.

• Option A: Option A is incorrect; TRAVERSE did not show a reduction in MACE with testosterone. It showed non-inferiority (no significant difference), not superiority or cardioprotection.
• Option B: Option B is incorrect; TRAVERSE was not terminated early for cardiovascular harm — it completed its follow-up. The TOM trial, not TRAVERSE, was stopped early for a cardiovascular signal, but TRAVERSE's design and population were different.
• Option C: Option C is incorrect; TRAVERSE did not show a significant increase in MACE with testosterone. The primary endpoint was non-inferior, meaning no significant difference was found. The subsequent FDA label modifications were not based on a MACE increase.
• Option D: Option D is incorrect; TRAVERSE did not demonstrate LDL reduction or coronary atherosclerosis regression with TRT. Testosterone's effects on lipids include a modest reduction in HDL cholesterol with injectable formulations, not LDL reduction; atherosclerosis regression was not a TRAVERSE endpoint.

ANSWER: B

Rationale:

Option B is correct. Testosterone replacement therapy suppresses spermatogenesis through a predictable, dose-dependent mechanism: exogenous testosterone feeds back at the hypothalamus to suppress GnRH pulsatility and at the pituitary to suppress LH and FSH secretion. Because intratesticular testosterone — which must be maintained at approximately 50 to 100 times the peripheral circulating concentration to support spermatogenesis — is dependent on LH-driven Leydig cell stimulation, the LH suppression from TRT collapses intratesticular testosterone to sub-spermatogenic levels. Additionally, FSH suppression impairs Sertoli cell function, which is required for germ cell development. Virtually all TRT regimens (injectable, transdermal, subcutaneous pellet) produce profound oligospermia or azoospermia in most men within 3 to 6 months of initiation. Recovery after TRT cessation typically takes 6 to 24 months and may be incomplete. The appropriate alternative for a hypogonadal man desiring fertility is human chorionic gonadotropin (hCG), which provides LH receptor stimulation to maintain intratesticular testosterone without suppressing the HPG axis, or clomiphene citrate (a SERM), which blocks hypothalamic estrogen receptor feedback and raises endogenous LH and FSH, stimulating both testosterone production and spermatogenesis.

• Option A: Option A is incorrect; exogenous testosterone does significantly suppress spermatogenesis even at standard replacement doses by the HPG axis suppression mechanism described. Intratesticular testosterone falls profoundly because Leydig cell stimulation (via LH) is suppressed, regardless of peripheral testosterone levels.
• Option C: Option C is incorrect; the HPG axis does not adapt to continue spermatogenesis during ongoing TRT. Suppression is persistent and progressive with continued administration, not transient.
• Option D: Option D is incorrect; TRT is not absolutely contraindicated in men of reproductive age — it is contraindicated in men who currently desire fertility, but once family planning is complete, TRT remains an appropriate treatment option.
• Option E: Option E is incorrect; spermatogenesis requires both FSH (for Sertoli cell support) and high intratesticular testosterone concentrations (for germ cell progression through meiosis). Neither alone is fully sufficient; TRT suppresses both pathways.

ANSWER: D

Rationale:

Option D is correct. Nasal testosterone gel (Natesto 4.5% gel) is applied to the nasal mucosa three times daily (morning, afternoon, and evening) and produces rapid transmucosal absorption with peak serum testosterone concentrations approximately 40 to 60 minutes after each application, followed by a rapid decline over the subsequent hours. This pharmacokinetic profile — multiple daily peaks of short duration — creates inter-dose intervals during which circulating testosterone returns toward lower levels, in contrast to the continuous androgen exposure produced by testosterone gels, patches, or injectable formulations with their prolonged elimination half-lives. The pulsatile GnRH secretion from the hypothalamus and the pulsatile LH and FSH secretion from the pituitary depend on periods of reduced androgen feedback; continuous androgen exposure suppresses this pulsatility and collapses intratesticular testosterone. Natesto's intermittent pharmacokinetics may partially preserve hypothalamic pulsatility and residual gonadotropin secretion during the lower-level inter-dose intervals, allowing some men — particularly those with residual Sertoli cell and germ cell function — to maintain a degree of spermatogenesis. This makes Natesto a consideration in hypogonadal men with residual fertility potential who require androgen therapy. The primary clinical limitation is the need for strict three-times-daily adherence.

• Option A: Option A is incorrect; Natesto does not produce CNS-selective absorption via the olfactory nerve that bypasses peripheral AR occupancy. Nasal mucosal absorption enters the systemic circulation; the drug is not neurotropic through the olfactory pathway in a pharmacologically meaningful way for testosterone.
• Option B: Option B is incorrect; supraphysiological testosterone levels produce negative, not positive, feedback on LH secretion through androgen receptor-mediated suppression at the hypothalamus and pituitary. There is no positive feedback mechanism for LH stimulation by androgens.
• Option C: Option C is incorrect; Natesto does not require hepatic CYP enzyme activation via nasal mucosal metabolism. It is absorbed systemically as testosterone from the mucosal surface and does not require bioactivation.
• Option E: Option E is incorrect; nasal administration does not restrict androgen receptor activity to the CNS. Once absorbed into the systemic circulation, testosterone distributes to all androgen receptor-expressing tissues, including the HPG axis, muscle, prostate, and skin.

ANSWER: A

Rationale:

Option A is correct. Both finasteride (type 2-selective) and dutasteride (dual type 1 and 2) reduce serum PSA by approximately 50% within 3 to 6 months of treatment initiation by reducing dihydrotestosterone (DHT)-mediated transcription of the KLK3 gene (encoding PSA) in prostatic epithelial cells. This predictable, quantifiable PSA suppression has critical implications for cancer screening: a measured PSA of 1.8 ng/mL in a man on finasteride corresponds to an estimated true PSA of approximately 3.6 ng/mL, a value that would typically prompt evaluation with prostate biopsy depending on patient age, race, and other risk factors. The clinical rule — double the measured PSA to estimate the equivalent off-treatment value — is established in the prescribing information for finasteride and in urologic and primary care guidelines, and failure to apply this correction can result in a clinically significant PSA elevation being missed. Additionally, any failure of PSA to fall by at least 50% after 6 months of 5AR inhibitor therapy, or any upward trend in PSA despite continued therapy, should prompt further investigation regardless of the absolute measured value, as this pattern suggests active prostate cancer driving PSA production despite DHT suppression.

• Option B: Option B is incorrect; PSA is an androgen-regulated gene product. Its expression is driven primarily by androgen receptor (AR) activation in prostatic epithelial cells, and reduction of intraprostatic DHT by 5AR inhibitors substantially suppresses PSA transcription and secretion.
• Option C: Option C is incorrect; finasteride decreases PSA by approximately 50%, not increases it. The described calculation (multiply by 0.7) is the opposite direction and would produce an artificially low estimate of true PSA.
• Option D: Option D is incorrect; the PSA reduction from finasteride is approximately 50%, not 90%. Dutasteride achieves approximately 50% PSA reduction as well despite its greater serum DHT suppression (~90–95%). A detectable PSA in a man on finasteride is expected and does not in itself indicate cancer; the relevant concern is a value that is higher than expected for the treatment duration or that rises over time.
• Option E: Option E is incorrect; PSA remains a valid screening tool in men on 5AR inhibitors when the correction factor is applied. Abandonment of PSA screening in favor of MRI alone is not current standard practice.

ANSWER: C

Rationale:

Option C is correct. The key pharmacological distinction between dutasteride and finasteride is isoform selectivity and the resulting degree of systemic DHT suppression. Finasteride is approximately 100-fold selective for type 2 5AR (SRD5A2), the predominant prostatic and scalp isoform, and reduces serum DHT by approximately 70% and intraprostatic DHT by over 90%. Dutasteride is a non-selective dual inhibitor of both type 1 5AR (SRD5A1, predominantly in liver, skin, and peripheral tissues) and type 2 5AR, achieving approximately 90% to 95% serum DHT suppression — substantially greater peripheral DHT suppression than finasteride. Despite this greater degree of serum DHT suppression, the clinical evidence from head-to-head comparative trials and systematic reviews has not demonstrated meaningfully superior BPH symptom reduction, flow rate improvement, or reduction in acute urinary retention or surgery rates with dutasteride compared to finasteride, likely because intraprostatic DHT suppression — which drives the therapeutic effect — is comparably achieved by both agents at the prostatic level (both suppress intraprostatic DHT by over 90%). The greater peripheral (type 1-mediated) DHT suppression with dutasteride does not appear to produce additional therapeutic benefit for BPH.

• Option A: Option A is incorrect; finasteride is NOT a dual inhibitor. Finasteride selectively inhibits type 2 5AR, while dutasteride is the dual inhibitor. The two agents are pharmacologically distinct in isoform selectivity, not equivalent.
• Option B: Option B is incorrect; it inverts the selectivity profiles of the two drugs entirely. Finasteride is the type 2-selective agent (70% DHT reduction); dutasteride is the dual inhibitor (90–95% DHT reduction).
• Option D: Option D is incorrect; dutasteride does not selectively inhibit type 1 5AR. Dutasteride inhibits both isoforms, and its efficacy in BPH derives primarily from its type 2 inhibition (the prostatic isoform), supplemented by additional peripheral DHT suppression via type 1 inhibition.
• Option E: Option E is incorrect; the pharmacological ceiling for serum DHT suppression is not 50%. Finasteride achieves approximately 70% serum DHT suppression and dutasteride achieves approximately 90–95%; a 50% ceiling is not supported by the clinical data.

ANSWER: E

Rationale:

Option E is correct. Both finasteride and dutasteride are absolutely contraindicated in women who are pregnant or may become pregnant. The teratogenic mechanism is well-established: in a male fetus (46,XY), DHT is essential for virilization of the external genitalia (urogenital sinus, genital tubercle) during the first trimester. A 5AR inhibitor that crosses to the fetus — either through maternal skin absorption from handling crushed tablets or through semen in a pregnant partner — reduces fetal DHT production and can produce ambiguous genitalia or incomplete virilization of a male fetus, analogous to the phenotype seen in congenital SRD5A2 deficiency. Women of childbearing potential must not handle crushed or broken tablets (intact coated tablets are safer because the coating prevents dermal absorption). The specific extended risk for dutasteride relates to its very long elimination half-life of approximately 3 to 5 weeks, compared to finasteride's half-life of 5 to 6 hours. Because dutasteride accumulates and is released slowly from body compartments (particularly adipose tissue), measurable dutasteride concentrations persist in semen for up to 6 months after a man discontinues therapy. A pregnant woman who has unprotected intercourse with a man who recently stopped dutasteride therefore faces a real, quantifiable fetal exposure risk. This is a pharmacokinetic distinction from finasteride, which clears the body and semen much more rapidly after discontinuation.

• Option A: Option A is incorrect; 5AR inhibitors cause feminization of male (XY) fetuses, not female (XX) fetuses. Female fetal development proceeds by default in the absence of androgens and is not impaired by reduced DHT.
• Option B: Option B is incorrect; the teratogenic risk extends beyond direct ingestion to dermal absorption from handling crushed tablets and to semen exposure; this is why the label specifically addresses not handling broken tablets and avoiding semen exposure during pregnancy.
• Option C: Option C is incorrect; the duration of risk from dutasteride is substantially longer than the treatment course due to its very long half-life and persistence in semen for up to 6 months post-discontinuation — the opposite of rapid elimination.
• Option D: Option D is incorrect; the teratogenic mechanism is genuine and pharmacologically well-understood: DHT is required for male external genital virilization, and its reduction by 5AR inhibitors produces real fetal risk. The FDA label precautions reflect an evidence-based teratogenic mechanism.

ANSWER: B

Rationale:

Option B is correct. Post-Finasteride Syndrome (PFS) is a clinical entity — controversial in terms of mechanism and prevalence but documented in clinical series and receiving increasing regulatory attention — in which men report persistence of sexual dysfunction (erectile dysfunction, reduced libido, ejaculatory dysfunction), neurological symptoms (cognitive impairment, fatigue), and psychiatric symptoms (depression, anxiety) after discontinuation of finasteride. The mechanistic basis of PFS is incompletely understood, but the most pharmacologically coherent proposed mechanism relates to neurosteroids: DHT and its metabolites, including 3-alpha-androstanediol (androstanediol) and subsequently allopregnanolone (3-alpha-hydroxy-5-alpha-pregnan-20-one), are neuroactive steroids that modulate gamma-aminobutyric acid type A (GABA-A) receptor function in the central nervous system, particularly at the neurosteroid binding site on the GABA-A receptor complex. Chronic 5AR inhibition by finasteride reduces production of these neurosteroids, and in some individuals this may produce lasting changes in GABAergic tone, receptor expression, or downstream neurochemical signaling that do not resolve when finasteride is stopped. Epigenetic changes in androgen receptor gene expression have also been proposed as a contributing mechanism. PFS is not universally accepted as a defined pharmacological syndrome, and its frequency in the overall population of finasteride users is debated, but its possibility warrants discussion with patients before initiating therapy.

• Option A: Option A is incorrect; irreversible AR downregulation in erectile tissue has not been established as the mechanism of PFS. Androgen receptor density is dynamically regulated and generally recovers after androgen restoration; permanent receptor loss is not a recognized pharmacological consequence of finasteride.
• Option C: Option C is incorrect; finasteride does not have a recognized withdrawal syndrome requiring tapering, analogous to corticosteroids. Finasteride does not suppress the hypothalamic-pituitary-adrenal axis and its discontinuation does not cause pharmacological withdrawal requiring dose reduction.
• Option D: Option D is incorrect; while epigenetic changes are a proposed component of PFS, permanent methylation silencing of the SRD5A2 gene producing congenital-equivalent deficiency has not been established as the mechanism. This is speculative beyond what the current evidence supports.
• Option E: Option E is incorrect; finasteride does not suppress pituitary LH and FSH secretion. It is a 5AR inhibitor, not an HPG axis suppressant. Testosterone levels are not significantly lowered by finasteride, and HPG axis suppression is not the mechanism of the symptoms described in PFS.

ANSWER: D

Rationale:

Option D is correct. Spironolactone is a synthetic steroidal compound primarily classified as a mineralocorticoid receptor (MR) antagonist, used as a potassium-sparing diuretic and antihypertensive at lower doses. At the higher doses used for anti-androgenic indications (100 to 200 mg daily for hirsutism, acne, or PCOS), spironolactone produces its anti-androgenic effect through three mechanisms: (1) competitive AR blockade — spironolactone and its active metabolite canrenone competitively displace testosterone and DHT from the androgen receptor; (2) inhibition of CYP17A1 (the 17-hydroxylase/17,20-lyase enzyme) at higher doses, which reduces adrenal androgen synthesis by impairing conversion of pregnenolone and progesterone to 17-hydroxy precursors and androgen precursors; and (3) possible enhancement of testosterone metabolic clearance. Because spironolactone is also an MR antagonist, it produces predictable mineralocorticoid-related adverse effects: hyperkalemia (from reduced renal potassium excretion), hypotension, and menstrual irregularity (from effects on the hypothalamic-pituitary-ovarian axis). Spironolactone is teratogenic in male fetuses through its AR-blocking and anti-androgenic activity, which can produce feminization of male offspring; contraception is required for women of childbearing potential taking spironolactone for any indication.

• Option A: Option A is incorrect; spironolactone has substantial MR antagonist activity — this is its primary pharmacological classification and its primary mechanism at lower doses. Its MR antagonism produces important adverse effects (hyperkalemia, hypotension) that cannot be separated from its clinical use.
• Option B: Option B is incorrect; spironolactone does not work primarily through LH suppression. Unlike cyproterone acetate (which has progestogenic and thus HPG-suppressive activity), spironolactone's anti-androgenic effects are mediated by direct AR blockade and steroidogenic enzyme inhibition.
• Option C: Option C is incorrect; spironolactone is not an androgen receptor agonist. It is an AR antagonist (competitive blocker) without meaningful intrinsic agonist activity at clinically used doses for hirsutism.
• Option E: Option E is incorrect; spironolactone does not bind the AR irreversibly. It is a competitive (reversible) receptor antagonist. Irreversible covalent AR binding would be a fundamentally different mechanism not applicable to spironolactone's pharmacology, and it would not be expected to produce effects lasting only until new receptor synthesis.

ANSWER: A

Rationale:

Option A is correct. Bicalutamide is a non-steroidal competitive androgen receptor (AR) antagonist with high binding affinity and no intrinsic agonist activity at physiologically relevant concentrations. Unlike the steroidal anti-androgens — cyproterone acetate (which has progestogenic activity) and spironolactone (which has mineralocorticoid and mild progestogenic-like activity) — bicalutamide has no progestogenic activity and therefore does not suppress gonadotropin secretion through the progesterone receptor-mediated HPG pathway. Instead, bicalutamide's AR blockade in the hypothalamus and pituitary removes testosterone's negative feedback on GnRH pulsatility and LH secretion, causing LH to rise. The elevated LH stimulates testicular Leydig cells to increase testosterone production, raising circulating testosterone to approximately 1.5 times above baseline. This testosterone rise partially offsets the AR blockade in peripheral tissues (including the prostate tumor), because higher circulating testosterone concentrations compete more effectively with bicalutamide for AR binding. This pharmacodynamic limitation — elevated testosterone partially overcoming AR blockade — is the rationale for combining bicalutamide with castration-level testosterone suppression (GnRH agonist or antagonist, or surgical orchiectomy) to achieve combined androgen blockade (CAB) and eliminate the testosterone escape. Bicalutamide at 50 mg is specifically used as flare protection during GnRH agonist initiation to block the transient testosterone surge that GnRH agonists produce before sustained suppression is achieved.

• Option B: Option B is incorrect; bicalutamide does not suppress gonadotropin secretion or achieve castrate testosterone levels. It is specifically distinguished from cyproterone acetate by this property.
• Option C: Option C is incorrect; bicalutamide is not a partial agonist at physiologically relevant concentrations in humans. Partial agonism has been described with early-generation anti-androgens (flutamide) in CRPC mutations, but bicalutamide's classification is as a competitive antagonist without clinically relevant intrinsic agonism.
• Option D: Option D is incorrect; bicalutamide does not selectively suppress LH while sparing FSH. If anything, both gonadotropins tend to rise during bicalutamide monotherapy because testosterone negative feedback is removed. Adrenal androgen stimulation by FSH via cross-reactivity is not an established pharmacological mechanism.
• Option E: Option E is incorrect; bicalutamide has good oral bioavailability (approximately 70%) and adequate systemic exposure at clinical doses. Inadequate bioavailability is not the pharmacological basis for its limitation as monotherapy.

ANSWER: C

Rationale:

Option C is correct. Enzalutamide's CNS adverse effect profile distinguishes it from first-generation AR antagonists such as bicalutamide and includes an important mechanism not shared by other anti-androgens: enzalutamide acts as a negative allosteric modulator of the gamma-aminobutyric acid type A (GABA-A) receptor, reducing the receptor's ability to open its chloride ion channel in response to GABA binding. GABA-A receptor activation by endogenous GABA provides the primary inhibitory counterbalance to neuronal excitability throughout the brain; negative allosteric modulation of GABA-A reduces inhibitory chloride conductance and lowers the seizure threshold. Clinical data from the enzalutamide development program identified an approximate 0.5% per year seizure rate, which led to the inclusion of seizure risk as a prominent warning in the prescribing information. Pre-existing seizure disorders, history of unprovoked seizure, CNS pathology, and concurrent use of drugs that lower the seizure threshold all represent predisposing risk factors that warrant individualized benefit-risk assessment and discussion with the patient before initiating enzalutamide. The CNS adverse effects also include fatigue and cognitive impairment. These CNS effects are absent with bicalutamide and represent a meaningful pharmacological difference between the two AR antagonists.

• Option A: Option A is incorrect; while enzalutamide is indeed a potent inducer of CYP3A4 and UGT1A1 (an important drug interaction to recognize), this pharmacokinetic induction mechanism is not the reason for the intrinsic seizure risk with enzalutamide. The GABA-A receptor pharmacodynamic mechanism is the direct CNS-level basis for the seizure concern, independent of any drug interactions.
• Option B: Option B is incorrect; enzalutamide does not act as a positive allosteric modulator of NMDA receptors. NMDA receptor-mediated excitotoxicity is not the established mechanism for enzalutamide-associated seizures.
• Option D: Option D is incorrect; the seizure risk with enzalutamide is not confined to combination therapy with GnRH agonists. It is an intrinsic CNS pharmacodynamic effect of enzalutamide itself and occurs regardless of concurrent castration.
• Option E: Option E is incorrect; there is no established mechanism of cumulative cortical atrophy from enzalutamide's AR blockade producing irreversible seizure threshold reduction. The seizure risk is related to the reversible GABA-A pharmacodynamic mechanism, not progressive cortical structural damage.

ANSWER: E

Rationale:

Option E is correct. AR-V7 (androgen receptor splice variant 7) is a constitutively active truncated variant of the androgen receptor that is transcribed from the AR gene but lacks the C-terminal ligand-binding domain (LBD) due to alternative splicing that joins exon 3 directly to cryptic exon CE3, skipping the LBD-encoding exons 4 through 8. Because AR-V7 lacks the LBD entirely, it is constitutively active — it does not require ligand (testosterone or DHT) to translocate to the nucleus and activate androgen-responsive gene transcription. This is important because all currently approved competitive AR antagonists — including bicalutamide, enzalutamide, apalutamide, and darolutamide — bind to the LBD of the androgen receptor to produce their antagonist effect. A receptor that lacks the LBD entirely cannot be blocked by any LBD-competitive antagonist. AR-V7 positivity in circulating tumor cells therefore predicts resistance to this entire mechanistic class and is associated with poor outcomes on AR-pathway-directed therapy. In AR-V7-positive mCRPC, taxane chemotherapy (docetaxel or cabazitaxel) retains anti-tumor activity because taxanes act on microtubules to prevent mitotic spindle formation, a mechanism entirely independent of androgen receptor status. Circulating tumor cell AR-V7 testing is clinically available and is used to guide treatment sequencing in CRPC.

• Option A: Option A is incorrect; AR-V7 does not have a mutated LBD that retains binding to certain antagonists. It lacks the LBD entirely, making it intrinsically resistant to all LBD-competitive antagonists including apalutamide and darolutamide. No competitive AR antagonist retains activity against a receptor with no LBD.
• Option B: Option B is incorrect; AR-V7 does not upregulate BRCA1/BRCA2 expression, and the rationale for switching to taxane in AR-V7-positive disease is not PARP inhibitor sensitivity. Taxane chemotherapy retains activity in AR-V7-positive CRPC, which is specifically contradicted by this option.
• Option C: Option C is incorrect; AR-V7 does not have an amplified LBD with increased antagonist binding affinity. It lacks the LBD entirely. The premise that AR antagonists paradoxically drive tumor growth through AR-V7 overactivation is mechanistically incorrect.
• Option D: Option D is incorrect; AR-V7 confers class-level resistance to all competitive AR antagonists, not only enzalutamide. Bicalutamide and abiraterone acetate (which targets androgen biosynthesis via CYP17A1 rather than the AR directly) are also ineffective in AR-V7-positive disease for different mechanistic reasons.

ANSWER: B

Rationale:

Option B is correct. The hepatotoxicity of oral anabolic-androgenic steroids is directly attributable to a specific structural modification: C17-alpha-alkylation, the addition of a methyl or ethyl group at the 17-alpha carbon of the steroid nucleus. Normal testosterone is metabolized in the liver by 17-beta-hydroxysteroid dehydrogenase enzymes, which oxidize the 17-beta hydroxyl group (converting testosterone to androstenedione) in preparation for conjugation and biliary excretion. The C17-alpha-alkyl group in oral AAS sterically blocks access of the 17-hydroxysteroid dehydrogenase enzyme to the adjacent C17-beta hydroxyl, preventing this first-pass hepatic oxidation and conferring oral bioavailability. However, this same structural impediment also impairs the hepatocyte's normal mechanisms for conjugating and excreting the steroid through bile, causing the drug to accumulate intracellularly in hepatocytes, impair bile acid transport (producing intrahepatic cholestasis), and, over time, cause cystic hepatocellular injury producing peliosis hepatis (blood-filled hepatic cysts). Decades of high-dose oral AAS use is associated with hepatocellular adenoma and hepatocellular carcinoma. Injectable AAS formulations such as nandrolone decanoate, boldenone undecylenate, and testosterone enanthate are esterified at the 17-beta position (not alkylated at 17-alpha), and once the ester is cleaved by serum esterases after systemic absorption, the released steroid undergoes normal hepatic metabolism without this structural impediment, producing no cholestatic or hepatocellular toxicity.

• Option A: Option A is incorrect; enterohepatic recirculation of oral AAS is not the established basis for hepatotoxicity. The structural chemical mechanism (C17-alpha-alkylation blocking 17-beta oxidation) is the correct explanation.
• Option C: Option C is incorrect; oral AAS hepatotoxicity is not caused by CYP3A4 inhibition leading to bile acid accumulation. This is a different mechanism from what is pharmacologically established for C17-alpha-alkylated steroids, which impair their own conjugation and biliary excretion, not bile acid metabolism through CYP3A4.
• Option D: Option D is incorrect; oral and injectable AAS do not have equivalent intrinsic hepatotoxicity. The C17-alpha-alkylation mechanism is a fundamental structural difference that produces a genuine pharmacological basis for the differential hepatotoxicity; this is not a confounding effect of dose differences in epidemiological data.
• Option E: Option E is incorrect; oral AAS are not prodrugs requiring UGT-mediated bioactivation, and UGT-generated reactive intermediates are not the established mechanism for their hepatotoxicity. UGT conjugation is normally a detoxification pathway, not a hepatotoxic bioactivation pathway for this drug class.

ANSWER: D

Rationale:

Option D is correct. Cardiovascular toxicity is the most life-threatening consequence of non-medical AAS use and represents the principal cause of AAS-related premature mortality in young men. The mechanisms are multiple and synergistic. First, supraphysiological androgens directly stimulate cardiac myocyte androgen receptors, driving cardiomyocyte hypertrophy and structural remodeling that produces pathological concentric left ventricular hypertrophy (LVH) — characterized by increased left ventricular wall thickness with a normal or reduced chamber volume, reduced diastolic compliance, impaired ventricular relaxation, and predisposition to both supraventricular and ventricular arrhythmia. This contrasts with physiological hypertrophy from athletic training, which produces eccentric hypertrophy (enlarged chamber volume with proportional wall thickening) and normal diastolic function. Second, AAS produce a markedly atherogenic lipid profile: dramatic reduction in high-density lipoprotein cholesterol (HDL-C) — the anti-atherogenic lipoprotein — and variable increase in low-density lipoprotein cholesterol (LDL-C), creating an environment that accelerates atherosclerotic coronary artery disease. Coronary CT imaging in young AAS users has demonstrated premature coronary calcification, and autopsy series have shown severe premature coronary atherosclerosis. Third, AAS produce direct cardiomyopathic changes including myocardial fibrosis, confirmed at autopsy in AAS-using athletes dying of sudden cardiac death, with dilated cardiomyopathy as an end-stage manifestation in some. Additional prothrombotic mechanisms include erythrocytosis-mediated hyperviscosity and possible effects on platelet aggregation and coagulation factors.

• Option A: Option A is incorrect; AAS-associated cardiomyopathy is not mediated through mineralocorticoid receptor activation. The mechanism involves direct androgen receptor effects on cardiomyocytes and adverse lipid changes, not mineralocorticoid pathways. Androgens are not converted to mineralocorticoids in adipose tissue.
• Option B: Option B is incorrect; QT interval prolongation is not the established primary cardiovascular toxicity mechanism of AAS. Arrhythmia does contribute to sudden cardiac death in AAS users, but it arises from structural substrate (LVH, fibrosis) rather than isolated QT prolongation from potassium channel downregulation.
• Option C: Option C is incorrect; AAS-associated LVH is pathological, not physiological athletic hypertrophy. It is not fully reversible after cessation in all cases — serial echocardiographic studies have demonstrated persistent structural changes and myocardial fibrosis after AAS discontinuation, and sudden cardiac death has occurred in former AAS users after cessation.
• Option E: Option E is incorrect; hematocrit elevation is one mechanism contributing to prothrombotic risk, but it is not the sole cause of AAS cardiovascular toxicity, and a specific threshold of 60% hematocrit is not the gating mechanism. The structural cardiomyopathy and dyslipidemia are independent mechanisms that operate regardless of hematocrit levels.